Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report
We report here the case of a patient with intracardiac metastasis secondary to malignant adrenocortical carcinoma, treated with magnetic resonance imaging-guided stereotactic radiotherapy.PMID:38341326 | DOI:10.1016/j.canrad.2023.06.033 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - February 10, 2024 Category: Cancer & Oncology Authors: M Michalet R T étreau J-L Pasqui é O Chabre D Azria Source Type: research
Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report
We report here the case of a patient with intracardiac metastasis secondary to malignant adrenocortical carcinoma, treated with magnetic resonance imaging-guided stereotactic radiotherapy.PMID:38341326 | DOI:10.1016/j.canrad.2023.06.033 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - February 10, 2024 Category: Cancer & Oncology Authors: M Michalet R T étreau J-L Pasqui é O Chabre D Azria Source Type: research
Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report
We report here the case of a patient with intracardiac metastasis secondary to malignant adrenocortical carcinoma, treated with magnetic resonance imaging-guided stereotactic radiotherapy.PMID:38341326 | DOI:10.1016/j.canrad.2023.06.033 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - February 10, 2024 Category: Cancer & Oncology Authors: M Michalet R T étreau J-L Pasqui é O Chabre D Azria Source Type: research
Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report
We report here the case of a patient with intracardiac metastasis secondary to malignant adrenocortical carcinoma, treated with magnetic resonance imaging-guided stereotactic radiotherapy.PMID:38341326 | DOI:10.1016/j.canrad.2023.06.033 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - February 10, 2024 Category: Cancer & Oncology Authors: M Michalet R T étreau J-L Pasqui é O Chabre D Azria Source Type: research
Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report
We report here the case of a patient with intracardiac metastasis secondary to malignant adrenocortical carcinoma, treated with magnetic resonance imaging-guided stereotactic radiotherapy.PMID:38341326 | DOI:10.1016/j.canrad.2023.06.033 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - February 10, 2024 Category: Cancer & Oncology Authors: M Michalet R T étreau J-L Pasqui é O Chabre D Azria Source Type: research
Quality control of postoperative radiotherapy for non-small cell lung cancer: A study of mediastinal shift
CONCLUSION: In conclusion, this study provides evidence that mediastinal shift is a potential complication during the PORT process for patients with N2 stage or R1-2 resection following radical resection of NSCLC. This shift affects about 20-30% of patients, manifesting as actual radiation damage to normal tissue and reducing the local control rate. Therefore, mid-term repositioning of the PORT and revision of the target volume and radiation therapy plan can aid in maintaining QA and QC during the treatment of NSCLC patients and may result in improved patient outcomes.PMID:38320903 | DOI:10.1016/j.canrad.2023.06.032 (Sourc...
Source: Cancer Radiotherapie - February 6, 2024 Category: Cancer & Oncology Authors: W Zhang Y Zhang W-W Ouyang S Fa Su Z Ma Q-S Li W Gang Yang X Xia Chen J Liu B Lu Source Type: research
Indication of radiotherapy for de novo metastatic cancer. The « Recommendations » Commission first issue
Cancer Radiother. 2024 Feb;28(1):1-2. doi: 10.1016/j.canrad.2024.01.001.NO ABSTRACTPMID:38307639 | DOI:10.1016/j.canrad.2024.01.001 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - February 2, 2024 Category: Cancer & Oncology Authors: I Latorzeff É Bayart D Azria Source Type: research
Radiotherapy in the management of lung oligometastases
Cancer Radiother. 2024 Feb;28(1):36-48. doi: 10.1016/j.canrad.2023.06.030. Epub 2024 Jan 16.ABSTRACTIn recent years, the development of both medical imaging and new systemic agents (targeted therapy and immunotherapy) have revolutionized the field of oncology, leading to a new entity: oligometastatic disease. Adding local treatment of oligometastases to systemic treatment could lead to prolonged survival with no significant impact on quality of life. Given the high prevalence of lung oligometastases and the new systemic agents coming with increased pulmonary toxicity, this article provides a comprehensive review of the cur...
Source: Cancer Radiotherapie - January 16, 2024 Category: Cancer & Oncology Authors: V Bourbonne A L évy J Khalifa D Antoni E Blais J Darr éon C Le P échoux D Lerouge P Giraud A Marguerit N Pourel F-G Riet S Thureau Source Type: research
Management of second ipsilateral breast tumor event: An advocacy for a randomized trial
Cancer Radiother. 2024 Jan 11:S1278-3218(23)00246-9. doi: 10.1016/j.canrad.2023.11.001. Online ahead of print.ABSTRACTFor a second ipsilateral breast tumor event, salvage mastectomy is the standard of care while second conservative treatment is a possible option. However, level 1 proofs are missing, leading to perform salvage mastectomy for patients who could receive second conservative treatment and consequently avoid psychological/quality of life salvage mastectomy deleterious impacts. A phase 3 randomized trial comparing salvage mastectomy to second conservative treatment is needed. Here we discuss what would be to us t...
Source: Cancer Radiotherapie - January 12, 2024 Category: Cancer & Oncology Authors: J-M Hannoun-L évi A Savignoni J-G F éron C Malhaire C Ezzili A Br édart P Loap Y Kirova Source Type: research
Management of oligometastatic/metastatic sarcomas and place of local treatments with focus on modern radiotherapy approaches
Cancer Radiother. 2024 Feb;28(1):93-102. doi: 10.1016/j.canrad.2023.06.029. Epub 2024 Jan 11.ABSTRACTSoft tissue sarcomas are a rare and heterogeneous disease. For localized disease, treatment is based on surgery and radiotherapy with or without chemotherapy depending on risk factors. Upfront metastases are present in 7 to 20% of cases, and are localized to the lungs in most of cases. Disseminated disease is generally considered incurable but in selected cases, aggressive local treatment of metastases allowed long survival. Treatment of primary tumour is often debated. Our purpose is to evaluate the literature concerning t...
Source: Cancer Radiotherapie - January 11, 2024 Category: Cancer & Oncology Authors: C Llacer-Moscardo L Moureau-Zabotto L Ollivier S Helfr é A Ducassou S Bonvalot M-P Sunyach P Sargos P Gillon N Firmin C Le P échoux J Thariat Source Type: research
Impact of adjuvant radiotherapy and chemotherapy on thymoma
CONCLUSION: Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.PMID:38182482 | DOI:10.1016/j.canrad.2023.08.009 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - January 5, 2024 Category: Cancer & Oncology Authors: J Dumont J Bou-Gharios A Keller I Chambrelant G Pamart C Mascaux P-E Falcoz D Antoni A Olland G A Pietta G No ël Source Type: research
Impact of adjuvant radiotherapy and chemotherapy on thymoma
CONCLUSION: Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.PMID:38182482 | DOI:10.1016/j.canrad.2023.08.009 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - January 5, 2024 Category: Cancer & Oncology Authors: J Dumont J Bou-Gharios A Keller I Chambrelant G Pamart C Mascaux P-E Falcoz D Antoni A Olland G A Pietta G No ël Source Type: research
Impact of adjuvant radiotherapy and chemotherapy on thymoma
CONCLUSION: Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.PMID:38182482 | DOI:10.1016/j.canrad.2023.08.009 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - January 5, 2024 Category: Cancer & Oncology Authors: J Dumont J Bou-Gharios A Keller I Chambrelant G Pamart C Mascaux P-E Falcoz D Antoni A Olland G A Pietta G No ël Source Type: research
Impact of adjuvant radiotherapy and chemotherapy on thymoma
CONCLUSION: Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.PMID:38182482 | DOI:10.1016/j.canrad.2023.08.009 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - January 5, 2024 Category: Cancer & Oncology Authors: J Dumont J Bou-Gharios A Keller I Chambrelant G Pamart C Mascaux P-E Falcoz D Antoni A Olland G A Pietta G No ël Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
